NVX-CoV2373 vaccine efficacy against hospitalization: A post hoc analysis of the PREVENT-19 phase 3, randomized, placebo-controlled trial

PREVENT-19, the pivotal phase 3 trial of the Novavax adjuvanted, recombinant spike protein COVID-19 vaccine (NVX-CoV2373), demonstrated that the vaccine was well tolerated and efficacious (vaccine efficacy, VE = 90%) for the prevention of symptomatic COVID-19. In the trial, participants were randoml...

Descripción completa

Detalles Bibliográficos
Autores principales: Marchese, Anthony M., Zhou, Xiang, Kinol, John, Underwood, Eddie, Woo, Wayne, McGarry, Alice, Beyhaghi, Hadi, Áñez, Germán, Toback, Seth, Dunkle, Lisa M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Authors. Published by Elsevier Ltd. 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10148668/
https://www.ncbi.nlm.nih.gov/pubmed/37127523
http://dx.doi.org/10.1016/j.vaccine.2023.04.054

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10148668/
https://www.ncbi.nlm.nih.gov/pubmed/37127523
http://dx.doi.org/10.1016/j.vaccine.2023.04.054

Ejemplares similares